Archives202520242023202220212020201920182017201620152014201320122011 September 14, 2016Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting Read More September 07, 2016ImmuPharma Invited to Open an Additional Site in Mauritius Read More September 07, 2016ImmuPharma Invited to Open an Additional Site in Mauritius Read More June 20, 2016Northland Capital Appointed as Joint Broker Read More June 08, 2016Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller Read More June 07, 2016First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Read More May 31, 2016Notification of Major Interest by Alto Invest to 4.15% Read More May 25, 2016Notification of Major Interest by Alto Invest Read More May 04, 2016PRELIMINARY RESULTS for the year ended 31 December 2015 Read More May 04, 2016Annual Report and Accounts – Notice of Annual General Meeting: 26 May 2016 Read More April 26, 2016Notification of Preliminary Results. Date: 4 May 2016 Read More March 10, 2016First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study Read More 12345…8
September 14, 2016Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting Read More
June 08, 2016Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller Read More
March 10, 2016First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study Read More
